### 1 TITLE: Interactive effects of bacterial vaginal colonization and HIV on pregnancy outcomes: A

### 2 Systematic Review and Meta-analysis

- 3 Dismas Matovelo<sup>1\*</sup>, Quinn Goddard<sup>2</sup>, Paul Sabuni<sup>1</sup>, Benson Kidenya<sup>1</sup>, Jennifer Downs<sup>1,3</sup>, Moke
- 4 Magoma<sup>4</sup>, Jeremiah Seni<sup>1</sup>, Kathleen Helen Chaput<sup>2</sup>
- <sup>5</sup> <sup>1</sup>Catholic University of Health and Allied Sciences, Weill Bugando School of Medicine, Mwanza,
- 6 Tanzania.
- 7 <sup>2</sup>University of Calgary, Cumming School of Medicine, Calgary, Canada
- 8 <sup>3</sup>Center for Global Health, Weill Cornell Medicine, New York, USA
- <sup>9</sup> <sup>4</sup>Engender Health, Dar es Salaam, Tanzania
- 10 Corresponding author: Dismas Matovelo; E-mail: <u>magonza@bugando.ac.tz</u>

### 11 Abstract

Background: The independent impact of HIV and bacterial vaginal colonization on pregnancy outcomes has been documented and is compounded by the burden of rapidly escalating antimicrobial resistance. However, the interactive effect of HIV and lower genital tract bacterial colonization, on pregnancy outcomes has not been thoroughly studied and is examined in our study.

17 Methods: We performed a systematic review and meta-analysis to quantitatively assess the interaction between HIV and vaginal bacterial colonization and associations with birth weight 18 19 and preterm birth. We searched Ovid MEDLINE, Ovid EMBASE, CINAHL, Scopus, Web of Science, 20 Cochrane Library, African Journals Online, and PubMed databases to identify studies published 21 up to December 31, 2023. We included observational reporting on vaginal colonization with 22 bacterial pathogens stratified by HIV status that reported pregnancy outcomes. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and used a 23 modified Newcastle-Ottawa Scale to assess study quality. Meta-analysis was conducted using 24 random-effects modeling in STATA Version 18. Pooled log-odds ratios were calculated. The study 25 protocol was registered in PROSPERO(CRD42023485123). 26

- 27 **Results:** We selected 13 studies, involving 6,073 pregnant women, from 5,807 studies identified.
- The overall pooled prevalence of bacterial colonization was 26%(95%CI:17.3-37.4). There was no
- significant effect of HIV status and vaginal colonization on birth weight(OR=1.2, 95%CI:-2.57-2.20,
- p=0.88) and borderline increased odds of preterm birth (OR=2.64, 95%CI:-0.01-1.94, p=0.05).
- 31 There was no significant association between HIV status and bacterial colonization(OR=1.08,

- 95%CI =-0.91-1.07), nor in antimicrobial resistance between pregnant women with HIV and those
   without.
- 34 **Conclusion:** Bacterial colonization is prevalent among pregnant women, but there is no clear
- 35 evidence to suggest that HIV and bacterial colonization interact to affect birth weight or preterm
- 36 birth. Research with large sample sizes, strict selection criteria, reliable and valid measurement,
- 37 adequate control for confounding variables, and birthweight and gestational age at delivery
- 38 assessment as continuous outcomes are still needed to provide robust evidence.
- Keywords: vaginal bacterial colonization, HIV, adverse pregnancy outcomes, preterm birth, low
  birth weight.
- 41

#### 42 INTRODUCTION

Bacterial genital infections are usually polymicrobial, affecting up to 50% of women during 43 44 pregnancy, intrapartum, and postpartum, and vary across trimesters due to factors such as hormonal changes, host genetics, behavioural, nutritional, and environment[1-3]. However, 45 46 despite hormonal changes during pregnancy, vaginal bacterial composition during gestation typically remains relatively stable among pregnant women not living with HIV[4]. In the setting 47 48 of HIV infection, which is characterized by an increase in pro-inflammatory responses and the release of cytokines, the integrity of the vaginal mucosal epithelium, the primary defence 49 50 mechanism is disrupted. Due to this loss in integrity of the vaginal mucosal epithelium, the vaginal 51 mucosa in HIV-infected pregnant women is characterized by a diverse microbiota predominantly 52 comprised of anaerobic species[3].

The occurrence of lower genital tract infections in pregnancy has significantly been reduced in high-income countries (HICs) in recent decades, due to optimization of surveillance and treatment[5]. However, such routine surveillance for common pathogens colonizing the vagina during pregnancy lack in most Low-Middle Income Countries (LMICs), along with the rapidly escalating burden of antimicrobial resistance (AMR) and variations in worldwide resistance patterns. As a result, empirical treatment has become difficult in LMICs[6, 7].

59 Approximately 70% of people living with HIV are in sub-Saharan Africa, and the global prevalence 60 of HIV among pregnant women is 7.2%[8, 9]. The dual impact of HIV infection and bacterial genital colonization may affect placental development and function, causing low birthweight 61 62 (LBW), small for gestational age (SGA), intrauterine growth restriction (IUGR), or preterm birth (PTB). Over the past decade it has become clear that although a healthy placenta has no 63 microbiome, it is still susceptible to pathogenic bacterial colonization, commonly group B 64 Streptococcus[10]. Placental bacterial colonization can affect placental development and 65 function, thereby impacting fetal growth and development. Disrupted placental function can lead 66 to SGA, IUGR, preterm labour and birth, rupture of membranes (ROM), chorioamnionitis, 67 68 neonatal sepsis, and LBW [10, 11]. These factors contribute to a series of short and long-term adverse effects such as neonatal sepsis and delayed child developmental milestones[10, 11]. 69

Both HIV and bacterial genital colonization may have an impact on pregnancy outcomes, especially birthweight, which is an important health indicator that has long-lasting impacts on infant and childhood development[11]. Globally, LBW and PTB are common, affecting an estimated 19.8 and 13.4 million births in 2020, respectively, with increased mortality risks particularly in the neonatal period, and long-term adverse health outcomes throughout life[12, 13]. However, there is a paucity of evidence on the association between HIV infection, lower genital tract pathogenic bacterial colonization and birth weight and conflicting evidence for

associations and potential interactions between bacterial colonization and HIV status withbirthweight.

Several individual studies attempting to estimate the disease burden of lower genital tract 79 bacterial colonization have reported that regardless of HIV status, Escherichia coli, Klebsiella. 80 pneumoniae and GBS are the most common organisms, with a wide prevalence range of 1.5%-81 73.5%[14, 15]. While some studies report a higher prevalence rate among pregnant women 82 infected with HIV[16], compared with those without, others report no differences[17-19]. To 83 bridge this knowledge gap, we performed a systematic review and meta-analysis to 84 85 quantitatively assess the prevalence of lower genital tract bacterial infections and their 86 association with pregnancy outcomes in HIV-infected and HIV-uninfected individuals. The results of this study provide insights into designing large prospective studies to decipher the associations 87 between lower genital tract bacteria colonization, HIV infection, and maternal and perinatal 88 89 outcomes. It will also help healthcare policymakers and various stakeholders ideally, seeking to standardize protocols for medical care and screening in this vulnerable population, with the 90 91 ultimate goal of reducing associated adverse maternal and perinatal outcomes.

#### 92 METHODS

93 **Objective:** The current review aimed to examine the interactive effects of lower genital tract 94 bacterial colonization in pregnancy and HIV infection on the primary outcomes of birthweight 95 and preterm birth. The secondary outcomes were intrauterine growth restriction (IUGR) and small for gestation age (SGA), as well as assessed the prevalence of antimicrobial resistance 96 97 (AMR) among HIV-infected vs -uninfected pregnant women as a tertiary outcome. This review was conducted following PRISMA guidelines (S2 Appendix) [20] and was registered with the 98 99 International Prospective Register of Systematic Reviews (PROSPERO)[21], registration number CRD42023485123, December 2023. 100

Search Strategy: We identified studies using electronic research databases and hand-searching methods. The comprehensive search strategy was developed in consultation with a research librarian and reviewed by two perinatal researchers (S1 Appendix). Our controlled vocabulary search included the following exploded keywords: *Vaginitis, "Genital Diseases, Female", "Reproductive Tract Infections", vagina, bacteria, Escherichia coli, "Klebsiella pneumoniae", "streptococcal infections", HIV, HIV Seropositivity, HIV Infections, HIV Seronegativity, Pregnancy, Pregnant Women, Pregnancy Trimester, Third, and pregnancy outcome.* 

108 We applied the search strategy in MEDLINE (Ovid), EMBASE (Ovid), CINAHL, Scopus, Web of 109 Science and the Cochrane Library to identify studies published regardless of year. We also 110 searched African Journals Online and PubMed databases for additional publications and used 111 Web of Science, Google and Google Scholar to search for grey literature. We modified indexing

112 terms such as Medical Subject Headings (MESH) or field tags according to each database and

113 linked searches using "AND" and "OR" Boolean operator terms as required. We hand-searched

by scanning references, "cited-by", and "similar articles" lists for eligible studies. No filters wereapplied.

Eligibility criteria: We initially included all quantitative observational studies that reported the prevalence of bacterial vaginal colonization published in English in peer-reviewed journals. Observational studies were included in the meta-analysis, that employed cohort, case-control, or cross-sectional designs. We included grey literature and published abstracts for a narrative summary in the review.

- Eligible studies involved pregnant women of any age who were tested for vaginal bacterial colonization at any point during their gestation. Studies must have had an exposure arm with pregnant women with HIV infection and a control arm with those without HIV. Studies must have measured birth weight and/or preterm birth as a pregnancy outcome, to document the differences in associations between vaginal bacterial colonization and birth weight among pregnant women with and without HIV. The outcomes involved aggregate counts for preterm birth (< 37 weeks completed gestation) and low birth weight (< 2500g).
- **Study selection:** We used Covidence software to collate our initial search results and remove duplicates before screening. Two independent authors (DM and QG) screened titles and abstracts of each article and assigned a 'yes', 'no', or 'maybe' to their eligibility for inclusion. Studies marked as "yes" or "maybe" underwent a full-text review, during which reasons for exclusion were documented. Any conflicts in decision-making were resolved by a third author (KHC). The Kappa index of the inter-observer agreement for title/abstract and full-text selection was high (0.96 and 0.73, respectively) as calculated by Covidence.
- Data Extraction and Critical Appraisal: Authors (DM and QG) conducted data extraction using 135 Covidence, which was then exported into Microsoft Excel 2023. We extracted the following 136 variables from the articles: a) first author's name, b) publication year, c) region/country, d) study 137 type/design, e) type of sample collected, f) sample size, g) sampling method, h) the prevalence 138 of vagina colonization, i) the microorganisms involved, j) pregnancy outcomes, and k) any other 139 results relevant to primary and secondary outcomes (if applicable). Two authors (DM and QG) 140 conducted the data extraction independently. Any discrepancies that emerged were resolved by 141 a third individual (KHC). If desired data were available for extraction, we contacted authors a 142 143 minimum of three times between January and June 2024 to obtain missing data points. Studies 144 were excluded from the meta-analysis if the authors were unreachable or unable to share the 145 required data.

146 **Quality assessment:** We used the modified Newcastle-Ottawa Scale (NOS) for quality assessment 147 since all eligible studies were observational designs[22]. We adapted the tool by adding topic-

- 148 specific criteria to make it more relevant to an epidemiological context. Specifically, we added
- 149 criteria for controlling additional confounders (such as co-morbidities), defining key variables
- 150 (such as vaginal colonization), and reporting sample, exposure, and control group details.

Quality assessment was performed by the first (DM) and second (QG) authors, and verified by the senior author (KHC). The NOS scale consists of eight sections that evaluate an article based on selection criteria, comparability, exposure assessment, and outcomes. Each included study received a score corresponding to the number of quality criteria satisfied, with scores of 0-5 considered low quality, 6-7 considered moderate quality, and 8-10 considered high quality. We included all articles in the systematic review but only studies with a minimum score of 6 and above were included in the meta-analysis.

158 Data analysis: A narrative analysis was performed to summarize the characteristics of the 159 included studies. We quantified the pooled interactive effect of bacterial vaginal colonization and 160 HIV on pregnancy outcomes, as well as the association between HIV and bacterial colonization, 161 using random-effects maximum likelihood forest plots to calculate log-odds ratios (OR) and their corresponding 95% confidence intervals. We further quantified the interaction using Cochrane's 162 163 Q value and Higgins I-squared  $(I^2)[23]$ , with a continuity correction of 0.5 for insufficient cell sizes[23]. We categorized  $l^2$  values of 0–40% as low heterogeneity; 50–70% as moderate 164 165 heterogeneity, and >70% as high heterogeneity[22]. The heterogeneity of studies reporting primary outcomes was further assessed using a Galbraith Plot with 95% confidence intervals. 166 167 Publication bias was represented graphically using a contour-enhanced funnel plot. We conducted all analyses using Stata version 17.0. 168

### 169 Results

- 170 We initially identified 7,005 identified studies (Medline = 981, Embase = 1,137, Web of Science
- 171 = 276, CINAHL = 4,075, Scopus = 459, Cochrane = 61, and grey literature (ProQuest) = 14; 1,198
- 172 duplicates were excluded). The first and second authors screened the 5,805 remaining
- abstracts, deeming 5,719 irrelevant. This left 86 studies for assessment. Two studies were
- 174 identified through hand-searching reference lists and were included in a full-text review (S1
- 175 Figure).

## 176 <u>S1 Figure: PRISMA flowchart diagram of the study selection</u>

177 The two authors had high inter-rater reliability (proportionate agreement = 0.97) and resolved

178 177 conflicting assessments through consensus. After a full-text review of 88 studies, 13 studies

- that met the inclusion criteria were included in the systematic review (Table in S1 Table). All
- identified studies were rated as 7 or higher by the first and second authors on the modified NOS.

181 Therefore, no studies were excluded from the meta-analysis based on quality assessment (S2 182 Table).

Since the majority of the included studies did not report all data points required for metaanalysis, we contacted the authors from all studies to request additional data. All included studies were conducted between 2006 and 2023 and published online between 2017 and 2023. Of the studies selected, four were cross-sectional, seven were cohort studies, and two were casecontrol studies. All except three were conducted in Africa. We found no other published systematic reviews on this topic.

- The overall sample size of all included studies was 6,073 participants, with individual study sample sizes ranging from 75 to 1,857. The prevalence of vaginal bacterial colonization ranged from 3.3% to 69.3% (Table in S1 Table). Testing and diagnostic criteria for bacterial colonization varied (S2 Table).

193

194

## 195 <u>S1 Table: Characteristics of the included studies</u>

s/	Author	Publicatio	County	Study	Total	<b>HIV Status</b>		Colonizati	95%CI	Туре	of
n	Name	n Year		Design	(N)	HIV+ n (%)	HIV- n (%)	on n (%)		bacteria	
1	Madrid., et al [24]	2018	Mozambiqu e	Cohort	320	117(36.6)	203(64.4)	120(37.5)	32.3%-42.9%	GBS & E. coli	
2	Nyemba., et al [25]	2022	South Africa	Cohort	619	486(78.5)	133(21.5)	198(32.0)	27.6%-34.9%	Chlamydia trachomatis, Neisseria gonorrhoea	
3	Gudza- Mugabe., et al [26]	2020	Zimbabwe	Cohort	356	42(11.8)	314(88.2)	88(24.7)	20.4%-29.3%	Bacterial vaginosis	
4	Njoku., et al [27]	2018	Nigeria	Cross- section al	168	84(50.0)	84(50.0)	18(10.7)	6.4%-15.9%	Group Streptococcu	B IS
5	Price., et al [28]	2021	Zambia	Cohort	363	85(23.4)	278(76.6)	221(60.9)	55.8%-65.8%	Bacterial vaginosis	
6	Biobaku., et al [29]	2017	Nigeria	Cross- section al	198	67(33.8)	131(66.2)	36(18.2)	13.1%-23.9%	Group Streptococcu	B IS
7	Smullin., et al [30]	2020	South Africa	Cohort	197	92(46.7)	105(53.3)	35(17.8)	12.7%-23.4%	Mycoplasma genitalium	
8	Short., et al [31]	2020	UK	Cohort	75	53(54.6)	22(45.4)	52(69.3)	58.4%-79.3%	Bacterial vaginosis	
9	Makinde., et al [32]	2022	Nigeria	Cross- section al	244	122(50.0)	122(50.0)	8(3.3)	1.4%-5.9%	Group Streptococcu	B IS
10	Morgan., et al [33]	2023	United States of America	Case- control	225	75(33.3)	150(66.7)	77(34.2)	28.2%-40.6%	Group Streptococcu	B IS
11	Ravindran, et al [34]	2021	Kenya	Cohort	1244	10(0.01)	1234 (99.99)	302(24.3)	21.9%-26.7%	Chlamydia trachomatis, Neisseria gonorrhoea	
12	Gray, et al [35]	2011	Malawi	Case- control	1857	402 (21.7)	1454 (78.3)	390 (21.0)	19.2%-22.9%	Group Streptococcu	B IS
13	El Beitune et al [36]	2006	Brazil	Cross- section al	207	101 (48.8)	106 (51.1)	35 (16.9)	12.1%-22.3%	Group Streptococcu	B IS
0ver	all				6073	1736(28.6)	4336(71.4)	1542(26.0)	17.3%-37.4%		

196

197

#### 198 S2 Table: Distribution of vaginal bacterial colonization among pregnant women

Author name	Total	Lab	Bacteria		HIV+	95% CI	HIV-		
	(N)	Method			n (%)		n (%)	95% CI	NOS
Madrid (2018)	120	Culture	E.coli		44(36.7)	28.2%-45.5%	76(63.3)	54.5%-71.8%	8
Nyemba (2022)	198	Culture	Chlamydia trachomatis Neisseria gonorrhoea	,	163(82.3)	76.7%-87.3%	35(17.7)	12.7%-23.3%	8
Gudza-Mugabe (2020)	88	PCR & DNA Sequencing	Bacterial vaginosis		18(20.5)	12.6%-29.6%	70(79.5)	70.4%-87.4%	7
Njoku (2018)	18	Culture	Group Streptococci	B us	13(72.2)	48.9%-90.9%	5(27.8)	9.1%-51.1%	8
Price (2021)	221	Metageno mic Sequencing	Bacterial vaginosis		85(38.7)	32.1%-45.0%	136(61.5)	55.0%-67.9%	8
Biobaku (2017)	36	Culture	Group Streptococci	B us	13(36.1)	21.1%-52.6%	23(63.9)	47.4%-78.9%	10
Smullin (2020)	35	Culture	mycoplasmo genitalium	מ	22(62.9)	46.1%-78.2%	13(37.1)	21.8%-53.9%	8
Short (2020)	52	DNA Sequencing	Bacterial vaginosis		42(80.8)	68.8%-90.5%	10(19.2)	9.5%-31.2%	7
Makinde (2022)	8	Culture	Group Streptococci	B us	4(50.0)	15.3%-84.7%	4(50.0)	15.3%-84.7%	8
Morgan (2023)	77	Culture	Group Streptococci	B us	31(40.3)	29.5%-51.5%	46(59.7)	48.5%-70.5%	7
Ravindran (2021)	302	Culture	Chlamydia trachomatis Neisseria gonorrhoea	,	4(0.01)	0.0%-3.0%	296(99.99)	97.0%-99.7%	8
Gray (2011)	390	Culture	Group Streptococci	B us	77(19.4)	15.9%-23.8%	313(21.7)	76.2%-84.1%	7
El Beitune (2006) 199	207	culture	Group streptococci	B JS	20(19.8%)	40.3%-73.2%	15(14.1%)	26.8%-59.7%	7

#### 200 Narrative analysis

No clear pattern of association between HIV, bacterial colonization, and low birth weight was observed in the included studies. For instance, Makinde *et al*[32] found no association between vaginal colonization and HIV status regarding low birth weight. Potentially, the very low prevalence of GBS within their sample (8/244), leading to low power in detecting an effect may explain the overall findings of this study. Similarly, Gudza-Mugabe *et al*[26] found no interaction

between vaginal microbiota and HIV positivity in determining birth outcomes. In contrast, Nyemba *et al*[25] found that the presence of *C. trachomatis* and *N. gonorrhoea* at the first antenatal care (ANC) visit in individuals with HIV leads to an increased risk of an adverse birth outcome. It is important to note that the the bacterial species examined varied across studies (i.e., *GBS*, *C. trachomatis*, *N. gonorrhoeae*).

211 Results for preterm birth were more consistent across the included studies. Nyemba *et al*[25], 212 Smullin et al[30], and Short et al[31] all found an elevated risk of preterm birth in analyzing the 213 interaction between vaginal colonization and HIV status. However, Gudza-Mugabe et al[26] and 214 Price et al[28] found that individuals with HIV infection were more likely to give birth 215 prematurely, regardless of vaginal microbiota, suggesting that the relationship between HIV 216 status and preterm birth was not modified by bacterial colonization. Ravindran et al[34] found that incident HIV infection, as well as C. trachomatis and N. gonorrhoeae infection, all 217 218 independently increased the risk of PTB. El Beitune et al[36] found no significant difference in the 219 prevalence of GBS carriage between HIV-positive and HIV-negative participants as well as no 220 significant difference in gestational age and birthweight of infants born to HIV-positive mothers compared with those born to HIV-negative mothers. The study did not stratify birth outcomes by 221 GBS status. Since most of these papers did not stratify by bacterial colonization status and HIV 222 223 status, the data included in our meta-analysis were obtained directly from the authors upon 224 request.

Benedetto et al[37] tested for BV as well as C. trachomatis, but did not stratify birth outcome by 225 HIV status with regards to colonization. The study found that cervicovaginal infections increased 226 227 the chance of preterm delivery. Foessleitner et al [38] investigated vaginal dysbiosis and BV in HIV-positive and HIV-negative women. While preterm birth was equally likely regardless of HIV 228 229 status, it was found that HIV-positive women were more likely to develop dysbiosis or BV. 230 Govender et al[39] analyzed the prevalence of genital mycoplasmas, ureaplasmas, and 231 Chlamydia trachomatis to HIV status. There was no association between HIV status and bacterial 232 colonization, as well as preterm delivery and colonization.

Several additional studies examined our variables of interest, but a lack of access to the original 233 234 dataset (e.g. destruction or loss of data) meant we were unfortunately not able to include them in our meta-analysis. Zenebe et al[40] documented STI status during pregnancy but did not 235 236 analyze the interaction between STI and HIV status on pregnancy outcomes. Looking at HIV 237 individually, they found that the mean birth weight was higher in babies born to HIV-uninfected 238 women, and women with HIV were more likely to give birth to a LBW infant than those without. Joachim et al[41] examined GBS colonization as well as HIV status, finding no significant 239 240 association between infant birthweight and GBS carriage, but did not examine differences by HIV status. Seale et al[42] found that women with GBS had a higher chance of stillbirth, but equal 241

likelihood of very preterm birth and very low birthweight than those without. It was found that 242 GBS carriage was reduced overall in women with HIV, but that women with HIV were more likely 243 244 to have more virulent CC17 GBS. Temmerman et al[43] tested for BV, C. trachomatis, N. gonorrhoeae, as well as HIV. It was found that mothers with HIV were more likely to give birth to 245 small for gestational age infants. Madrid et al[24] tested for Group B Streptococcus and found 246 247 that mothers with HIV were at no higher risk of GBS colonization than those without. Morgan et 248 al[33] found that HIV-positive individuals had a higher chance of preterm birth, but that the 249 likelihood of GBS colonization did not differ between individuals with and without HIV.

- 250 Only one study, Gudza-Mugabe *et al*[26], analyzed small for gestational age (SGA), and found no
- 251 difference in SGA between mothers with and without HIV. None of the included studies analyzed
- 252 intrauterine growth restriction.

#### 253 Meta-Analysis

Primary Outcomes: Of the studies with adequate data to be included in the meta-analysis, five examined low birth weight as an outcome, with an overall sample of 3,520 individuals, 784

- (22.2%) of whom had bacterial colonization and 1,284 (36.4%) were pregnant women with HIV
- infection. Six studies examined preterm birth, with a total sample of 5,164 individuals, 1,356
- 258 (26.3%) of which had bacterial colonization and 1,372 (26.6%) were pregnant women with HIV.
- 259 Low Birthweight: We observed no significant interactive effect between HIV status and vaginal
- 260 bacterial colonization on low birth weight (log OR= 0.19, 95% CI= -2.57, 2.20, equivalent OR=1.21,
- 261 p = 0.88) and a high degree of heterogeneity between the studies ( $I^2 = 88.73\%$ ; Q = 19.84, p = 0.00),
- 262 indicating low reliability for the pooled estimate (S2 Figure).
- 263 S2 Figure: Interactive effect of HIV and bacterial colonization on birthweight.

264 Preterm Birth: Overall, we found a borderline-significant increased log-odds of preterm birth

among individuals with HIV and vaginal bacterial colonization, compared to those without either

266 (log OR= 0.97, 95% CI=-0.01, 1.94, p=0.05; equivalent OR: 2.64, p = 0.05). Moderate heterogeneity 267 was observed between the included studies ( $l^2$  = 53.76%; Q = 16.78, p = 0.02), indicating

268 moderate reliability of the estimate. One study [34] reported a log-OR less than 0 (indicating the

- 269 protective effect of HIV and Colonization), while the majority of studies (75%) trended toward
- 270 increased odds of preterm birth with HIV and bacterial colonization compared to no HIV or
- colonization (S3 Figure).
- 272 The methods of calculating gestational age varied, potentially impacting the estimate of preterm
- birth. Three studies [25, 26, 35] used an estimate of last menstrual period (LMP), one study [28]
- used ultrasound dating, and one study [34] employed a combination of ultrasound, LMP and
- fundal height. The two remaining studies [30, 31] did not specify the method of GA calculation.

276 S3 Figure: Interactive effect of Hiv and bacterial colonization on preterm birth.

### 277 Heterogeneity

- We lacked enough studies in the pooled analysis of low birthweight to effectively evaluate heterogeneity or publication bias graphically for this outcome. The Galbraith plot of preterm birth studies confirms overall low-moderate heterogeneity, with all 8 studies lying within the 95% Cl region (S4 Figure). The regression line significantly deviates from the null-effect line, with 75% of
- the studies positioned above the no-effect line.

## 283 <u>S4 Figure: Galbraith plot of precision in studies examining low birthweight</u>

## 284 Publication Bias

The included studies produce a right-skewed, asymmetrical funnel (S5 Figure), suggesting the presence of publication bias. This bias likely stems from the underreporting of null or protective findings, potentially leading to an overestimation of the effect in the included studies. Therefore, although 7 out of 8 studies lie within the 90% confidence interval, these findings should be interpreted cautiously due to the relatively low number of studies included in this assessment (<10).

291 <u>S5 Figure: Publication bias contour-enhanced funnel plot</u>

Secondary Outcomes: The birth outcomes examined in the included studies varied considerably, and we had insufficient data to generate meaningful pooled estimates for our secondary outcomes of intrauterine growth restriction (IUGR), and small for gestational age (SGA). This was defined as a birth weight of less than the 10<sup>th</sup> percentile for gestational age.

**Tertiary Outcome:** In assessing antimicrobial resistance (AMR), we found that six different types of bacterial isolates were examined in the included studies, with the highest pooled prevalence being bacterial vaginosis (33.9%), examined in three studies. Six of the included studies tested for Group B Streptococcus (GBS) which had a pooled prevalence of 20.2%. Other bacterial species were less commonly examined (S3 table). All studies testing AMR evaluated *GBS*, facilitating meaningful pooled estimates of the association between HIV and *GBS* in terms of AMR.

303

- 304
- 305

<sup>302</sup> 

#### 306 <u>S3 Table: Vaginal colonization bacterial isolate types</u>

Bacterial isolates	No. of studies	Total N	Cases	Prevalence, 95% CI
Group B Streptococcus [27, 29, 32, 33, 35, 36]	6	3129	632	20.2%. 18.8%-21.6%
Mycoplasma genitalium [30]	1	197	35	17.8%, 12.7%-23.4%
Bacterial vaginosis [26, 28, 31]	3	794	269	33.9%, 30.6%-37.2%
Neisseria Gonorrhoea [25]	1	619	35	5.7%, 4.0%-7.6%
Chlamydia trachomatis [25]	1	619	158	25.5%, 22.2%-29.0%
Escherichia coli [24]	1	320	52	16.2%, 12.4%-20.5%
Any STI in pregnancy [25, 30]	2	816	311	38.1%, 34.8%-41.5%
Chlamydia trachomatis & Neisseria gonorrhoea [34]	1	1244	302	24.3%, 21.9%-26.7%

307

#### 308 <u>S6 Figure: Association between HIV status and Bacterial Colonization</u>

309 There was no significant association between HIV status and bacterial colonization across 310 included studies (log-OR=0.08 [-0.91, 1.07]; equivalent OR=1.08) (S6 Figure). Likewise, we found no statistically significant difference in log odds of AMR between HIV-positive and HIV-negative 311 individuals for each antibiotic examined for resistance (Ampicillin: log-OR=0.47[-0.94, 1.87]; 312 equivalent OR=1.60, Ceftriaxone: log-OR=0.28[-1.77, 2.33]; equivalent OR=1.32, Clindamycin: 313 log-OR=0.48[-1.28, 2.24], equivalent OR=1.61, Erythromycin: logOR=1.14[-0.83, 3.11], equivalent 314 OR=3.12, Penicillin: log-OR=0.42 [-0.94, 1.77], equivalent OR=1.42). Heterogeneity was low to 315 moderate for most antibiotics, except for erythromycin ( $I^2$ =75.79). (S7 Figure: A-E) We were 316 unable to pool proportions of antimicrobial resistance across antibiotic types, due to aggregate 317 318 reporting of AMR, and lack of individual participant data.

319 **A**.

- 320 **B.**
- 321 **C.**
- 322 **D.**
- 323 **E.**

324 <u>S7 Figure: Pooled log odds of AMR among those with and without HIV, by antibiotics</u>

325

326

#### 327 Discussion

This systematic review and meta-analysis found no significant interactive effects between HIV 328 329 and vaginal bacterial colonization on low birthweight in the included studies (OR=1.21, p=0.88). We found the odds of preterm birth among those with HIV and bacterial colonization was 2.64 330 331 times greater than those without HIV or colonization, albeit borderline non-significant (OR=2.64, p=0.05). The majority of studies tended toward increased odds of preterm birth with HIV and 332 333 colonization, preterm birth remains a rare outcome, and even with pooling study results, we may have lacked the statistical power to adequately assess the effect. Unfortunately, due to both data 334 335 availability limitations and limitations in the available data, we could not model the pooled effect 336 on gestational age or birth weight outcomes as continuous variables, which would have improved 337 statistical power. Future studies should report incidences of both continuous and categorical outcome measures to allow for a more nuanced assessment of this relationship. 338

339 We found no previous systematic review or meta-analysis which has assessed the potential 340 interactive relationship between HIV status, vaginal bacterial colonization and LBW, though when assessed separately, systematic reviews and meta-analyses show that HIV-exposed neonates are 341 at higher risk for GBS neonatal disease[44], and that low birth weight is more prevalent in 342 neonates born from women living with HIV infection[45]. Our findings regarding preterm birth 343 344 are similar to those from previous systematic review and meta-analyses that demonstrated increased odds of preterm birth among individuals with HIV and vaginal bacterial colonization 345 346 compared to those without [45]. Results from Ravindran et al [34] study of a decreased risk of preterm birth in HIV-positive individuals with colonization differed from other studies. However, 347 348 this finding may be attributable to the small sample size of HIV-positive participants in this study (n = 10) and the corresponding higher likelihood of type II error, as well as the fact that they did 349 not recruit based on HIV status, and only retained incident cases of HIV in their originally HIV-350 351 negative cohort. Although there was only moderate heterogeneity among our included studies, 352 varying patterns of pathogenic bacteria colonizing the lower genital tract, and the fact that bacterial vaginosis is a clinical syndrome caused by a group of bacterial species, rather than a 353 354 single pathogen type, may have contributed to the observed heterogeneity in studies. Additionally, some methodological differences in the studies could contribute to our results, 355 356 including differential methods and criteria for testing for bacterial colonization among groups with and without HIV, differing methods of defining preterm birth, and selection and inclusion 357 358 criteria.

We also found that the overall odds of bacterial colonization did not differ significantly between those living with HIV and those without. This finding is congruent with a systematic review and meta-analysis conducted by Cools *et al.* which showed no difference between HIV status and rectovaginal colonization[44]. Our meta-analysis included 13 studies, however, the high degree

of heterogeneity between studies limits the reliability of this estimate. Further, we found 363 moderate to high risk of bias in most studies included in our analysis, due to methodological 364 365 limitations. However, few of these studies were designed to assess the association between HIV status and bacterial colonization as a primary outcome. Future prospective cohort studies with 366 strong selection and recruitment strategies, along with adequate confounding control in the 367 368 analysis are necessary to confirm whether HIV status impacts the odds of bacterial colonization 369 in pregnancy. Similarly, we did not observe a significant difference in the odds of antimicrobial 370 resistance (AMR) among those living with HIV and those without. However, the sample sizes for each antibiotic were small, and due to a lack of individual-level data, we were unable to pool the 371 analysis across antibiotic types, which limited statistical power. Although the specific antibiotics 372 373 to which resistance exists is important to understand, future studies should also consider the inclusion of an analysis of whether pregnant individuals with colonization are resistant to one or 374 375 more antibiotics, to allow an examination of the association between HIV status and resistance. In a meta-analysis conducted in the general population among people living with HIV, those with 376 377 HIV were more likely to be colonized with resistant bacterial strains than people without and there was an increased risk of AMR in those living with HIV, across a range of bacterial pathogens 378 379 and in multiple drug classes[46]. However, it remains unclear if similar patterns persist during 380 pregnancy. Moreover, bacteria colonizing the lower genital tract in high-income countries (HICs) tend to be predominantly Gram-positive. In Low and Middle-Income Countries (LMICs), Gram-381 negative bacteria are predominant and are more highly associated with neonatal sepsis and 382 mortality, highlighting a need for further research taking into account this geographical context. 383

384 Although this systematic review and meta-analysis presents up-to-date global evidence on the prevalence of vaginal bacterial colonization and pregnancy outcomes, it is not without 385 386 limitations. The majority of the included studies are from Africa where the prevalence of HIV 387 infection is high (60% of the HIV-infected population is in Africa). Comparatively, there is a lack 388 of studies originating from Asia, Europe, and North and South America. The generalizability of the findings is therefore limited to African populations, as the overall sample is not representative 389 390 of a global population. Further, most included studies recruited participants and/or laboratory samples through hospitals or from mothers who presented for routine ANC or delivery at tertiary 391 hospitals. This could potentially skew the estimated prevalence towards urban settings and 392 underestimate the associations that might exist in rural areas or smaller local health centres 393 serving individuals of a more vulnerable socioeconomic status. The risk of antimicrobial-resistant 394 395 organisms likely differs in these tertiary hospitals compared to rural settings and may be higher due to greater exposure to antimicrobials in people seeking care at tertiary hospitals. 396

One of the strengths of this study is the inclusion of studies examining direct vaginal colonization,
 whereas several previous studies evaluated rectal colonization only, meaning previous evidence
 may include pathogens that are not present in the lower genital tract, and thus may not influence

400 pregnancy to the same extent[47, 48]. Although the large overall sample size of included studies 401 in our review is a strength, the limited number of studies with complete data for inclusion in the 402 meta-analyses of each outcome coupled with the moderate to high heterogeneity of studies 403 limits the reliability of estimates, and our findings should be interpreted with caution. A further 404 limitation of our findings is that there is likely some publication bias toward those with significant 405 findings in the direction of elevated odds of adverse outcomes, which further limits the reliability 406 of our findings.

The result of this meta-analysis indicates that there is still no clear evidence of whether HIV 407 408 infection and bacterial colonization interact to affect low birth weight or preterm birth. There is 409 still no global consensus on routine screening of pregnant women for lower genital tract pathogenic bacterial colonization, and the variations in methods used across the included studies 410 are likely diminishing the reliability of our findings. Working toward a standardized vaginal 411 412 bacterial screening during pregnancy, regardless of HIV status, could act to improve the identification of bacterial infections and potentially reduce any associated adverse outcomes. 413 Further research conducted with large sample sizes, strong selection criteria, reliable and valid 414 measurement, and adequate control for confounding variables, along with the assessment of 415 birthweight and gestational age at delivery as continuous outcomes are desirable to strengthen 416 the evidence in this area of research. 417

Abbreviations: AMR-Antimicrobial Resistance; AMSTAR-Assessing the Methodological Quality of 418 419 Systematic Reviews; ANC-Antenatal Care; CINAHL-Cumulative Index to Nursing and Allied Health Literature; CMA-Comprehensive Meta-Analysis; CI- Confidence Interval; HICs- High-Income 420 421 Countries; HIV-Immunodeficiency Virus; IUGR-Intrauterine Growth restrictions; LBW-Low Birth Weight; LMICs-Low-Middle Income Countries; MESH-Medical Subject Headings; OR-Odds ratio; 422 423 NIH-National Institutes of Health; NOS-New Castle-Ottawa Scale; PCR-Polymerase Chain 424 Reaction; PRISMA-Preferred Reporting Items for Systematic Reviews and Meta-Analyses; SGA-425 Small for Gestation; SD-Standard Deviation; SSA-Sub-Saharan Africa.

426 **Contributions:** DM and KHC developed the protocol and were involved in the design, selection 427 of study, data extraction, quality assessment, statistical analysis, results interpretation and 428 development of the initial and final drafts of the manuscript; JS, JD, and MM conceived the 429 project, designed the study and did several reviews of the manuscripts; DM, QG and KHC were 430 involved in screening, quality assessment, data extraction, statistical analysis and revising 431 subsequent manuscript drafts; PS and BK were involved in data analysis, synthesis and review of 432 the manuscript. All authors read and approved the final draft of the manuscript.

Ethics approval: Ethical approval was not required since this study relied solely on published
data. However, permission for publication was sought from the CUHAS/BMC Research & Ethical
Committee (CREC).

436 Data availability: The data analyzed during the current systematic review and meta-analysis are
437 available and made public (S3 Appendix).

Acknowledgements: We would like to thank the staff of the University of Calgary, particularly
Sophie Petit from the Indigenous, Local & Global Health (ILGH) office and Dianne Lorenzetti from
the University Library, for their assistance with developing the search strategy. We also extend
our gratitude to all the authors of the studies included in this systematic review and metaanalysis.

### 443 **References**

- Tumuhamye, J., Steinsland, H., Tumwine, J.K., Namugga, O., Mukunya, D., Bwanga, F., et al.,
   Vaginal colonisation of women in labour with potentially pathogenic bacteria: a cross sectional
   study at three primary health care facilities in Central Uganda. BMC infectious diseases, 2020.
   20(1): p. 98.
- Sweeney, E.L., Kallapur, S.G., Gisslen, T., Lambers, D.S., Chougnet, C.A., Stephenson, S.A., et al., *Placental infection with Ureaplasma species is associated with histologic chorioamnionitis and adverse outcomes in moderately preterm and late-preterm infants.* The Journal of infectious
  diseases, 2016. 213(8): p. 1340-1347.
- Juliana, N.C., Peters, R.P., Al-Nasiry, S., Budding, A.E., Morré, S.A. and Ambrosino, E., *Composition*of the vaginal microbiota during pregnancy in women living in sub-Saharan Africa: a PRISMAcompliant review. BMC pregnancy and childbirth, 2021. 21(1): p. 1-15.
- 4. Abdool Karim, S.S., Baxter, C., Passmore, J.A.S., McKinnon, L.R. and Williams, B.L., *The genital tract*456 *and rectal microbiomes: their role in HIV susceptibility and prevention in women.* Journal of the
  457 International AIDS Society, 2019. **22**(5): p. e25300.
- 4585.Charlier, C., O. Disson, and M. Lecuit, *Maternal-neonatal listeriosis*. Virulence, 2020. **11**(1): p. 391-459397.
- 460 6. Tumuhamye, J., Steinsland, H., Bwanga, F., Tumwine, J.K., Ndeezi, G., Mukunya, D., et al., *Vaginal*461 *colonization with antimicrobial-resistant bacteria among women in labor in central Uganda:*462 *prevalence and associated factors.* Antimicrobial Resistance & Infection Control, 2021. 10(1): p. 1463 11.
- Wang, P., Tong, J.J., Ma, X.H., Song, F.L., Fan, L., Guo, C.M., et al., Serotypes, antibiotic
  susceptibilities, and multi-locus sequence type profiles of Streptococcus agalactiae isolates
  circulating in Beijing, China. PLoS One, 2015. 10(3): p. e0120035.
- 4678.Ozim, C.O., Mahendran, R., Amalan, M. and Puthussery, S., Prevalence of human468immunodeficiency virus (HIV) among pregnant women in Nigeria: a systematic review and meta-469analysis. 2023. 13(3): p. e050164.
- 470 9. Manyahi, J., Jullu, B.S., Abuya, M.I., Juma, J., Ndayongeje, J., Kilama, B., et al., *Prevalence of HIV*471 *and syphilis infections among pregnant women attending antenatal clinics in Tanzania, 2011.* BMC
  472 Public Health, 2015. **15**(1): p. 501.
- 473 10. De Goffau, M.C., Lager, S., Sovio, U., Gaccioli, F., Cook, E., Peacock, S.J., et al., *Human placenta has*474 *no microbiome but can contain potential pathogens.* Nature, 2019. **572**(7769): p. 329-334.
- 475 11. Waldorf, K.M.A. and R.M. McAdams, *Influence of infection during pregnancy on fetal*476 *development.* Reproduction, 2013. 146(5): p. R151-R162.
- 47712.Okwaraji, Y.B., Bradley, E., Ohuma, E.O., Yargawa, J., Suarez-Idueta, L., Requejo, J., et al., National478routine data for low birthweight and preterm births: Systematic data quality assessment for

479 *United Nations member states (2000–2020).* BJOG: An International Journal of Obstetrics & 690 Gynaecology, 2023.

- 481 13. Ohuma, E.O., Moller, A.B., Bradley, E., Chakwera, S., Hussain-Alkhateeb, L., Lewin, A., et al.,
  482 *National, regional, and global estimates of preterm birth in 2020, with trends from 2010: a*483 *systematic analysis.* The Lancet, 2023. 402(10409): p. 1261-1271.
- Birhane Fiseha, S., Mulatu Jara, G., Azerefegn Woldetsadik, E., Belayneh Bekele, F. and
  Mohammed Ali, M., Colonization Rate of Potential Neonatal Disease-Causing Bacteria, Associated *Factors, and Antimicrobial Susceptibility Profile Among Pregnant Women Attending Government Hospitals in Hawassa, Ethiopia.* Infection and Drug Resistance, 2021. 14: p. 3159.
- 488 15. Kamgobe, E., Grote, S., Mushi, M.F., Wilson, D., Gandye, L., Bader, O., et al., *Multi-drug resistant*489 *facultative pathogenic bacteria colonizing the vagina of pregnant women with premature rupture*490 *of membrane, Tanzania.* East Africa Science, 2020. 2(1): p. 29-35.
- Mitima, K.T., Ntamako, S., Birindwa, A.M., Mukanire, N., Kivukuto, J.M., Tsongo, K., *Prevalence of colonization by Streptococcus agalactiae among pregnant women in Bukavu, Democratic Republic of the Congo*. The Journal of Infection in Developing Countries, 2014. 8(09): p. 1195-1200.
- 49417.Ernest, A.I., Ndaboine, E., Massinde, A., Kihunrwa, A. and Mshana, S., Maternal vaginorectal495colonization by Group B Streptococcus and Listeria monocytogenes and its risk factors among496pregnant women attending tertiary hospital in Mwanza, Tanzania. Tanzania Journal of Health497Research, 2015. **17**(2).
- Shah, M., Aziz, N., Leva, N. and Cohan, D., *Group B Streptococcus colonization by HIV status in pregnant women: prevalence and risk factors.* Journal of women's health, 2011. 20(11): p. 17371741.
- 19. Dauby, N., Adler, C., Miendje Deyi, V.Y., Sacheli, R., Busson, L., Chamekh, M., et al. *Prevalence, risk factors, and serotype distribution of group B Streptococcus colonization in HIV-infected pregnant women living in Belgium: a prospective cohort study.* in *Open Forum Infectious Diseases.* 2018.
   Oxford University Press US.
- 50520.Page, M.J., McKenzie, J.E., Bossuyt, P.M., Boutron, I., Hoffmann, T.C., Mulrow, C.D., et al., *The*506*PRISMA 2020 statement: an updated guideline for reporting systematic reviews.* International507journal of surgery, 2021. **88**: p. 105906.
- 50821.Schiavo, J.H., PROSPERO: an international register of systematic review protocols. Medical509reference services quarterly, 2019. **38**(2): p. 171-180.
- 510 22. Wells GA, S.B., O'Connell D, Peterson J, Welch V, Losos M, et al., *The Newcastle-Ottawa Scale*511 (*NOS*) for assessing the quality of nonrandomised studies in meta-analyses. 2014.
- 51223.Thompson, D.M. and Y.D. Zhao, Choosing statistical models to assess biological interaction as a513departure from additivity of effects. arXiv preprint arXiv:2301.03349, 2023.
- Madrid, L., Maculuve, S.A., Vilajeliu, A., Sáez, E., Massora, S., Cossa, A., et al., *Maternal carriage*of group B Streptococcus and Escherichia coli in a district hospital in Mozambique. The Pediatric
  infectious disease journal, 2018. **37**(11): p. 1145-1153.
- 517 25. Nyemba, D.C., Peters, R.P., Medina-Marino, A., Klausner, J.D., Ngwepe, P., Myer, L., et al., *Impact*518 of aetiological screening of sexually transmitted infections during pregnancy on pregnancy
  519 outcomes in South Africa. BMC Pregnancy and Childbirth, 2022. 22(1): p. 194.
- 520 26. Gudza-Mugabe, M., Havyarimana, E., Jaumdally, S., Garson, K.L., Lennard, K., Tarupiwa, A., et al.,
   521 *Human immunodeficiency virus infection is associated with preterm delivery independent of* 522 *vaginal microbiota in pregnant African women.* The Journal of infectious diseases, 2020. 221(7):
   523 p. 1194-1203.
- Njoku, C., C. Emechebe, and A. Agbakwuru, prevalence and determinants of anogenital
   colonization by Group B Streptococcus infection among HIV positive and negative women in
   Calabar, Nigeria. Int J Women's Health Reprod Sci, 2017. 6(1): p. 11-7.

- Price, J.T., Vwalika, B., France, M., Ravel, J., Ma, B., Mwape, H., et al., *HIV-associated vaginal microbiome and inflammation predict spontaneous preterm birth in Zambia*. Scientific Reports,
   2022. 12(1): p. 8573.
- Biobaku Oluwafunmilola, R., Olaleye Atinuke, O., Adefusi Olorunwa, F., Adeyemi Babalola, A.,
  Onipede Anthony, O., et al., *Group B streptococcus colonization and HIV in pregnancy: A cohort study in Nigeria.* Journal of Neonatal-Perinatal Medicine, 2017. **10**(1): p. 91-97.
- 53330.Smullin, C.P., Green, H., Peters, R., Nyemba, D., Qayiya, Y., Myer, L., et al., Prevalence and534incidence of Mycoplasma genitalium in a cohort of HIV-infected and HIV-uninfected pregnant535women in Cape Town, South Africa. Sexually transmitted infections, 2020. 96(7): p. 501-508.
- 53631.Short, C.E.S., Brown, R.G., Quinlan, R., Lee, Y.S., Smith, A., Marchesi, J.R., et al., Lactobacillus-537depleted vaginal microbiota in pregnant women living with HIV-1 infection are associated with538increased local inflammation and preterm birth. Frontiers in Cellular and Infection Microbiology,5392021. 10: p. 596917.
- Makinde, O., B. Okusanya., and G. Osanyin., *Group B Streptococcus vaginal colonization in pregnant women living with HIV infection: prevalence and antibiotic susceptibility at HIV referral centers in Lagos, Nigeria.* The Journal of Maternal-Fetal & Neonatal Medicine, 2022. **35**(25): p.
  9098-9104.
- 54433.Morgan, J.A., Hankins, M.E., Callais, N.A., Albritton, C.W., Vanchiere, J.A., et al., Group B545Streptococcus rectovaginal colonization and resistance patterns in HIV-positive compared to HIV-546negative pregnant patients. American Journal of Perinatology, 2023. 40(14): p. 1573-1578.
- Ravindran, J., Richardson, B.A., Kinuthia, J., Unger, J.A., Drake, A.L., Osborn, L., et al., *Chlamydia*, *gonorrhea*, and incident HIV infection during pregnancy predict preterm birth despite treatment.
  The Journal of infectious diseases, 2021. 224(12): p. 2085-2093.
- 55035.Gray, K.J., Kafulafula, G., Matemba, M., Kamdolozi, M., Membe, G. and French, N., Group B551Streptococcus and HIV infection in pregnant women, Malawi, 2008–2010. Emerging infectious552diseases, 2011. 17(10): p. 1932.
- 553 36. El Beitune, P., Duarte, G., Maffei, C.M.L., Quintana, S.M., Rosa, A.C.J.D.S., Silva, E., et al., *Group B* 554 *Streptococcus carriers among HIV-1 infected pregnant women: prevalence and risk factors.* 555 European Journal of Obstetrics & Gynecology and Reproductive Biology, 2006. **128**(1-2): p. 54-58.
- Benedetto, C., Tibaldi, C., Marozio, L., Marini, S., Masuelli, G., Pelissetto, S., et al., *Cervicovaginal infections during pregnancy: epidemiological and microbiological aspects*. The Journal of
   Maternal-Fetal & Neonatal Medicine, 2004. 16(2): p. 9-12.
- 55938.Foessleitner, P., Petricevic, L., Boerger, I., Steiner, I., Kiss, H., Rieger, A., et al., *HIV infection as a*560risk factor for vaginal dysbiosis, bacterial vaginosis, and candidosis in pregnancy: A matched561case-control study. Birth, 2021. **48**(1): p. 139-146.
- 39. Govender, S., Theron, G.B., Odendaal, H.J. and Chalkley, L.J., *Prevalence of genital mycoplasmas, ureaplasmas and chlamydia in pregnancy.* Journal of Obstetrics and Gynaecology, 2009. 29(8): p.
  698-701.
- 40. Zenebe, A., B. Eshetu, and S. Gebremedhin, *Association between maternal HIV infection and birthweight in a tertiary hospital in southern Ethiopia: retrospective cohort study.* Italian Journal of Pediatrics, 2020. 46: p. 1-9.
- Joachim, A., Matee, M.I., Massawe, F.A. and Lyamuya, E.F., *Maternal and neonatal colonisation*of group B streptococcus at Muhimbili National Hospital in Dar es Salaam, Tanzania: prevalence,
  risk factors and antimicrobial resistance. BMC public Health, 2009. 9: p. 1-7.
- Seale, A.C., Koech, A.C., Sheppard, A.E., Barsosio, H.C., Langat, J., Anyango, E., et al., *Maternal colonization with Streptococcus agalactiae and associated stillbirth and neonatal disease in coastal Kenya*. Nature microbiology, 2016. 1(7): p. 1-10.

- 574 43. Temmerman, M., Plummer, F.A., Mirza, N.B., Ndinya-Achola, J.O., Wamola, I.A., Nagelkerke, N.,
  575 et al., *Infection with HIV as a risk factor for adverse obstetrical outcome.* Aids, 1990. 4(11): p. 1087576 1094.
- 577 44. Cools, P., van de Wijgert, J.H., Jespers, V., Crucitti, T., Sanders, E.J., Verstraelen, H., et al., *Role of*578 *HIV exposure and infection in relation to neonatal GBS disease and rectovaginal GBS carriage: a*579 *systematic review and meta-analysis.* Scientific Reports, 2017. 7(1): p. 13820.
- 580 45. Xiao, P.L., Zhou, Y.B., Chen, Y., Yang, M.X., Song, X.X., Shi, Y., et al., Association between maternal
  581 *HIV infection and low birth weight and prematurity: a meta-analysis of cohort studies.* BMC
  582 pregnancy and childbirth, 2015. 15: p. 1-11.
- 583 46. Olaru, I.D., Tacconelli, E., Yeung, S., Ferrand, R.A., Stabler, R.A., Hopkins, H., et al., *The association*584 *between antimicrobial resistance and HIV infection: a systematic review and meta-analysis.*585 Clinical Microbiology and Infection, 2021. 27(6): p. 846-853.
- 47. Marando, R., Seni, J., Mirambo, M.M., Falgenhauer, L., Moremi, N., Mushi, et al., *Predictors of the extended-spectrum-beta lactamases producing Enterobacteriaceae neonatal sepsis at a tertiary hospital, Tanzania.* International Journal of Medical Microbiology, 2018. 308(7): p. 803-811.
- Kovacs, D., Silago, V., Msanga, D.R., Mshana, S.E., Seni, J., Oravcova, K, et al., *The hospital environment versus carriage: Transmission pathways for third-generation cephalosporin-resistant bacteria in blood in neonates in a low-resource country healthcare setting.* Scientific Reports,
  2022. 12(1): p. 8347.

593



## S1 Figure PRISMA Flowchart



## S2 Figure effect of HIV and colonization on birthweight



# S4 Figure Galbraith plot if precision in birthweight

Figure 3: In	teracti	ve E	fect o	f HIV	and Bacterial Co	olonization	n on Preterm Birth	ı
	Color	nized	Uncold	nized			Log odds-ratio	Weight
Study	HIV+	HIV-	HIV+	HIV-			with 95% CI	(%)
Nyemba 2022	20	2	6	8		-	2.32 [ 0.66, 3.99]	15.01
Gudza-Mugabe 2020	4	4	6	30		-	1.96 [ 0.30, 3.63]	15.02
Price 2021	8	6	2	8			1.24 [ -0.53, 3.02]	14.16
Smullin 2020	4	0	6	10			2.49 [ -0.65, 5.64]	7.00
Short 2020	6	0	0	0			2.56 [ -2.30, 7.43]	3.45
Ravindran 2021	4	80	6	218			-1.40 [ -4.31, 1.51]	7.85
Gray 2011	12	44	58	156	-		-0.27 [ -0.97, 0.43]	23.78
ElBeitune 2006	4	8	2	8			0.46 [ -1.37, 2.29]	13.74
Overall					+		0.97 [ 0.01, 1.94]	
Heterogeneity: $\tau^2 = 0.9$	90, l <sup>2</sup> = 5	3.76%	5, H <sup>2</sup> = 2	2.16				
Test of $\theta_i = \theta_i$ : Q(7) = 1	6.78, p	= 0.02	2					
Test of $\theta = 0$ : z = 1.97,	p = 0.0	5						
					-5 0	5	10	
Random-effects REML	model							

# S3 Figure effect of HIV and colinization on preterm birth



medRxiv preprint doi: https://doi.org/10.1101/2024.09.18.24313939; this version posted September 19, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

## S5 Figure publication bias contour-enhanced funnel plot



### Log-odds of bacterial colonization with HIV infection versus without HIV

Random-effects REML model

## S6 Figure association between HIV and colonization

Ampicillin													
Study	Resi: HIV+	stant HIV-	Sens HIV+	sitive HIV-		Log odds-ratio with 95% CI	Weight (%)						
Njoku 2018	11	4	2	1		0.32 [ -2.34, 2.98]	28.00						
Makinde 2022	4	0	0	4		4.39 [ 0.26, 8.53]	11.60						
Morgan 2023	0	0	18	20		0.10 [ -3.87, 4.07]	12.56						
Madrid 2018	0	0	26	42		0.47 [ -3.48, 4.42]	12.69						
Biobaku Oluwafunmilola 2017	1	3	12	20		-0.59 [ -2.96, 1.79]	35.15						
Overall					+	0.47 [ -0.94, 1.87]							
Heterogeneity: $\tau^2 = 0.00$ , $I^2 = 0.00$	00%, H <sup>2</sup>	= 1.0	D										
Test of $\theta_i = \theta_i$ : Q(4) = 4.27, p = 0	0.37												
Test of θ = 0: z = 0.65, p = 0.52													
				-	5 0 5	10							

Ceftriaxone Sensitive Weight Resistant Log odds-ratio HIV+ HIVwith 95% CI Study HIV+ HIV-(%) Njoku 2018 -0.32 [ -2.98, 2.34] 27.08 2 4 1 11 Makinde 2022 4.39 [ 0.26, 8.53] 16.46 4 0 0 4 Madrid 2018 42 0.47 [ -3.48, 4.42] 17.47 0 26 0 -1.12 [ -2.64, 0.41] 38.99 Biobaku Oluwafunmilola 2017 3 11 10 12 0.28 [ -1.77, 2.33] Overall Heterogeneity: τ<sup>2</sup> = 2.20, I<sup>2</sup> = 52.17%, H<sup>2</sup> = 2.09 Test of  $\theta_i = \theta_i$ : Q(3) = 6.20, p = 0.10 Test of  $\theta = 0$ : z = 0.27, p = 0.79-5 0 5 10 Random-effects REML model

Clindamycin												
Study	Resi HIV+	stant HIV-	Sens HIV+	sitive HIV-		Log odds-ratio with 95% CI	Weight (%)					
Njoku 2018	7	3	6	2		-0.25 [ -2.35, 1.84]	26.98					
Makinde 2022	3	2	1	2		1.10 [ -1.90, 4.09]	19.29					
Morgan 2023	10	0	8	11			19.45					
Biobaku Oluwafunmilola 2017	5	14	8	9		-0.91 [ -2.31, 0.48]	34.27					
Overall					-	0.48 [ -1.28, 2.24]						



Erythromycin												
Study	Resi HIV+	stant HIV-	Sens HIV+	sitive HIV-						Log odds-ratio with 95% Cl	Weight (%)	
Njoku 2018	4	1	9	61					_	3.30 [ 1.00, 5.60]	23.76	
Makinde 2022	3	0	1	4		+	-	-		3.04 [ -0.45, 6.54]	16.70	
Morgan 2023	10	10	8	10	-	-	+			0.22 [ -1.05, 1.50]	30.61	
Biobaku Oluwafunmilola 2017	3	9	10	14	_	-				-0.76 [ -2.30, 0.78]	28.94	
Overall										1.14 [ -0.83, 3.11]		
Heterogeneity: $\tau^2 = 2.88$ , $I^2 = 75$	.79%, H	<sup>12</sup> = 4.	13									
Test of $\theta_i = \theta_j$ : Q(3) = 10.49, p =	0.01											
Test of $\theta$ = 0: z = 1.13, p = 0.26												
					-2	ò	2	4	6			
Random-effects REML model												

				Peni	cillin		
Study	Resistant HIV+ HIV-		Sensitive HIV+ HIV-			Log odds-ratio Weight with 95% CI (%)	t
Njoku 2018	10	4	3	2		0.51 [ -1.62, 2.64] 40.16	-
Makinde 2022	4	2	0	2			
Madrid 2018	0	0	26	42		- 0.47 [ -3.48, 4.42] 11.70	
Biobaku Oluwafunmilola 2017	1	3	12	20		-0.59 [ -2.96, 1.79] 32.41	
<b>Overall</b> Heterogeneity: $\tau^2 = 0.00$ , $I^2 = 0.00$	00%, H <sup>2</sup>	= 1.00	D		+	0.42 [ -0.94, 1.77]	
Test of $\theta_i = \theta_j$ : Q(3) = 1.75, p = 0	.63						
Test of $\theta = 0$ : z = 0.60, p = 0.55							
				-	5 Ó	5	
Random-effects REML model							